Please check your internet connection and try again.
# Tradjenta (linagliptin)
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which leads to increased insulin release and decreased glucagon secretion in a glucose-dependent manner.
## Primary Indications
* Type 2 diabetes mellitus, as an adjunct to diet and exercise, to improve glycemic control.
## Adult Dosing
* **Usual dose:** 5 mg orally once daily.
* Can be taken with or without food.
* No dose adjustment is needed based on renal impairment.
## Pediatric Dosing
* Linagliptin is not approved for use in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* Hypersensitivity to linagliptin or any excipients in the formulation.
## Adverse Effects
* **Common:** Nasopharyngitis, diarrhea, cough.
* **Serious:** Hypoglycemia (especially when used in combination with other antidiabetic agents like sulfonylureas or insulin), hypersensitivity reactions (including anaphylaxis, angioedema, urticaria, rash), severe and disabling arthralgia, bullous pemphigoid.
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort):** May decrease linagliptin exposure and efficacy. Monitor glucose control closely.
* **Sulfonylureas and Insulin:** Increased risk of hypoglycemia. Consider a lower dose of the sulfonylurea or insulin.
## Monitoring
* **HbA1c:** Regularly monitor glycemic control.
* **Renal function:** Although no dose adjustment is needed, consider monitoring as part of routine diabetes care.
* **Signs and symptoms of hypersensitivity reactions and arthralgia:** Educate patients to report these promptly.
* **Signs and symptoms of hypoglycemia:** Especially when co-administered with other glucose-lowering agents.
## Clinical Pearls
* Linagliptin is unique among DPP-4 inhibitors as it does not require dose adjustment for renal or hepatic impairment, making it a convenient option for patients with these comorbidities.
* It is primarily eliminated unchanged in the feces, with minimal renal excretion.
* Patient education regarding the risk of hypoglycemia, especially when used in combination therapy, is crucial.
* Advise patients to report any severe or persistent joint pain.
***
**Disclaimer:** This information is intended for healthcare professionals and is a summary. Always consult the current official prescribing information and institutional protocols for complete and up-to-date guidance before making any treatment decisions.
